Q-omics provides the consensus-scored KRT23 profile across patient tissues and cancer cell-line models. KRT23 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, KRT23 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, KRT23 RNA expression shows 13,210 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, HNSC, and TGCT as cancer lineages where KRT23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT23 survival associations across molecular data types. KRT23 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT23 RNA expression–survival associations across cancer types. High KRT23 expression shows unfavorable associations in BLCA, LGG, GBM, MESO and READ, but favorable associations in UCEC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for KRT23 RNA expression.
This table summarizes KRT23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KRT23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT23 shows lower tumor expression in HNSC, BRCA and KICH and higher tumor expression in COAD, BLCA and READ. The HNSC box plot shows higher KRT23 RNA expression in normal versus tumor tissue (log2 FC = −2.646, t-test p < 0.001).
This table shows molecular features associated with KRT23 in patient tissues and cancer cell lines. In patient samples, KRT23 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
